NASDAQ: ALZNAlzamend Neuro Inc Stock
$0.66-0.01 (-1.49%)
Updated Apr 30, 2025
ALZN Price
$0.66
Fair Value Price
$0.02
Market Cap
$4.35M
52 Week Low
$0.64
52 Week High
$15.06
P/E
-0.22x
P/B
1.26x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$4.23M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.21
Operating Cash Flow
-$7M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ALZN Overview
Alzamend Neuro, Inc., is a clinical-stage biopharmaceutical company developing products to treat neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its pipeline includes AL001 for the treatment of Alzheimer's, other neurodegenerative diseases, and psychiatric disorders, and AL002, to restore patients' immunological systems to combat Alzheimer's. The company was founded in 2016 and is headquartered in Tampa, FL.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ALZN's potential to beat the market
- ALZN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ALZN
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ALZN news, forecast changes, insider trades & much more!
ALZN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ALZN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ALZN ($0.66) is overvalued by 2,863.69% relative to our estimate of its Fair Value price of $0.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ALZN ($0.66) is not significantly undervalued (2,863.69%) relative to our estimate of its Fair Value price of $0.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALZN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALZN due diligence checks available for Premium users.
Valuation
ALZN fair value
Fair Value of ALZN stock based on Discounted Cash Flow (DCF)
Price
$0.66
Fair Value
$0.02
Overvalued by
2,863.69%
ALZN ($0.66) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALZN ($0.66) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALZN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ALZN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
-162.28x
Market
29.18x
ALZN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.26x
Industry
4.45x
ALZN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ALZN's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.0M
Profit Margin
0%
ALZN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.2M
Liabilities
$725.9k
Debt to equity
0.21
ALZN's short-term assets ($3.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALZN's short-term assets ($3.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALZN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.4M
Investing
$0.0
Financing
$688.7k
ALZN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ALZN vs Biotech Stocks
Alzamend Neuro Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.